Abstract
The clinical effect of bleomycin was first observed in the treatment of squamous cell carcinomas in 1966. The size of this kind of tumor decreases with bleomycin treatment and even cases of complete cure have been reported. Among the tumors belonging to this group, the well-differentiated type responds to bleomycin treatment with a very high frequency. There are patients who have lived more than 10 years after several courses of treatment with bleomycin alone. The rate of cure from squamous cell carcinoma has been increased by the simultaneous use of bleomycin and radiation or by applying radiation after bleomycin treatment. Most Hodgkin’s lymphomas are very sensitive to bleomycin treatment. This tumor decreases in size rapidly with such treatment, and complete cures have been obtained by a combination of bleomycin with other antitumor agents. Even a daily dose of bleomycin as small as 1 mg exhibits a therapeutic effect on Hodgkin’s lymphoma. Recently, treatment by a combination of bleomycin and a Vinca alkaloid or a platinum compound was found to have a therapeutic effect on testis tumors. Bleomycin treatment does not suppress immune function and does not damage bone marrow; however, the amount of bleomycin used in one course of treatment is presently limited to 200-300 mg per person because of its pulmonary toxicity. Therefore, a bleomycin with lower pulmonary toxicity could exhibit stronger therapeutic action against the tumors described above than the bleomycin presently employed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
S.K., Carter, T., Ichikawa, G. Mathe, and H., Umezawa,Fundamental and clinical studies of bleomycin. GANN Monograph on Cancer Research, No. 19 (Japanese Cancer Association), University of Tokyo Press (1976).
K., Maeda, H., Kosaka, K., Yagishita, and H., Umezawa, J. Antibiot. (Tokyo), Ser. A, 9, 82 (1956).
W.T., Bradner and M.H., Pindell, Nature (London), 196,682 (1962).
H., Umezawa, M., Hori, M., Ishizuka and T., Takeuchi, J. Antibiot. (Tokyo), Ser. A, 15, 274 (1962).
N., Tanaka, H., Yamaguchi, and H., Umezawa, J. Antibiot. (Tokyo), Ser. A, 16, 86 (1963).
M., Ishizuka, H., Takayama, T., Takeuchi, and H., Umezawa, J. Antibiot. (Tokyo), Ser. A, 19, 260 (1966).
M., Ikekawa, F., Iwami, H., Hiranaka, and H., Umezawa, J. Antibiot. (Tokyo), Ser., A, 17, 194(1964).
H. Umezawa, K. Maeda, T. Takeuchi, and Y. Okami, J. Antibiot, (Tokyo), Ser. A, 19, 200 (1966).
M., Ishizuka, H., Takayama, T., Takeuchi, and H., Umezawa, J. Antibiot. (Tokyo), Ser. A, 20, 15 (1967).
H., Umezawa, Y., Suhara, T., Takita, K., Maeda, J. Antibiot (Tokyo), Ser. A, 19,210 (1966).
H., Umezawa, M., Ishizuka, K., Kimura, J., Iwanaga, and T., Takeuchi, J. Antibiot. (Tokyo), 21, 592 (1968).
H., Umezawa, Pure Appl. Chem., 28, 665 (1971).
H. Umezawa, Fundamental and clinical studies of bleomycin. GANN Monograph on Cancer Research, No. 19 (Japanese Cancer Association), University of Tokyo Press, PP. 3–36 (1976).
T., Takita, Y., Muraoka, T., Yoshioka, A., Fujii, K., Maeda, and H., Umezawa, J. Antibiot. (Tokyo), 25, 755 (1972).
H., Naganawa, Y., Muraoka, T., Takita, H., Umezawa, J. Antibiot. (Tokyo), 30, 388 (1977).
Y., Muraoka, A., Fujii, T., Yoshioka, T, Takita, and H., Umezawa, J. Antibiot. (Tokyo), 30, 178 (1977).
T., Takita, Y., Muraoka, A., Fujii, H., Itoh, K., Maeda, and H., Umezawa, J. Antibiot. (Tokyo), 25, 197 (1972).
H., Nakamura, T., Yoshioka, T., Takita, H., Umezawa, Y., Muraoka, and Y., Iitaka, J. Antibiot. (Tokyo), 29, 762 (1976).
J.H., Coats and J., Roeser,J. Bacteriol., 105, 880 (1971).
Y., Muraoka, H., Kobayashi, A., Fujii, M., Kunishima, T., Fujii, Y.,akayama, T., Takita, and H., Umezawa, J. Antibiot. (Tokyo), 29, 853 (1976).
J.C., Dabrowiak, F.T., Greenaway, W.E., Longo, M., VanHusen, and S.T., Crooke, Biochim. Biophys. Acta,517 , 517 (1978).
A., Falaschi and A., Kornberg, Fed. Proc., 23, 940 (1964).
K., Nagai, H., Suzuki, N., Tanaka, and H., Umezawa, J. Antibiot. (Tokyo), 22, 569 (1969).
K., Nagai, H., Suzuki, N., Tanaka, and H., Umezawa, J. Antibiot. (Tokyo), 22, 624 (1969).
K. Nagai, H. Suzuki, N. Tanaka, and H. Umezawa, J. Antibiot. (Tokyo), Biophys. Acta, 179, 165 (1969).
H., Umezawa, H., Asakura, and M., Hori, J. Antibiot. (Tokyo), 26, 521 (1973).
H., Asakura, M., Hori, and H., Umezawa, J. Antibiot. (Tokyo), 28, 587 (1975).
C.W., Haidle, Mol. Pharmacol., 7, 645 (1971).
C.W., Haidle, M.T., Kuo, and K.K., Weiss, Biochem. Pharmacol., 21, 3308 (1972).
C.W., Haidle, K.K.,Weiss, and M.T., Kuo,Mol. Pharmacol., 8, 531(1972).
C.W., Haidle, K.K., Weiss, and M.L.,MaceJr., Biochem. Biophys. Res. Commun., 48, 1179 (1972).
M.T., Kuo and C.W., Haidle, Biochim. Biophys. Acta, 335, 109 (1973); Biophys. J., 13, 1296 (1973).
W.E.G., Müller, Z., Yamazaki, H., Breter, and R.K., Zahn, Eur. J. Biochem., 31, 518(1972).
W.E.G., Müller, Z., Yamazaki, and R.K., Zahn, Biochem. Biophys. Res. Commun., 46, 1667 (1972).
W.E.G., Müller, Z., Yamazaki, J.E., Zoellner, and R.K., Zahn, FEBS Lett., 31, 217 (1973).
Z. Yamazaki, W.E.G. Müller, and R.K. Zahn, Biochim. Biophys. Acta, 308, 412 (1973).
S.L., Ross and R.E., Moses, Biochemistry, 17, 581(1978).
M., Chien, A.P., Grollman, and S.B., Horowitz, Biochemistry, 16, 3641(1977).
E.A., Sausville, J., Peisach, and S.B.,Horowitz, Biochem. Biophys. Res. Commun., 73,814(1976).
J. Bearden and C.W. Haidle, Biochem. Biophys. Res. Commun., 65,371(1975).
W.E.G., Müller, H.J., Rohde, R., Steffen, A., Maidhof, and R.K., Zahn, Cancer Lett., 1. 127 (1976).
Y. Yagoda and H. Krakoff, Fundamental and clinical studies on bleomycin. GANN Monograph on Cancer Research, No. 19 (Japanese Cancer Association), University of Tokyo Press, pp. 255–268 (1976).
T., Ichikawa, A., Matsuda, K., Yamamoto, M., Tsubosaki, T., Kaihara, K., Sakamoto, and H, Umezawa, J. Antibiot. (Tokyo), Ser. A, 20, 149 (1967).
H., Umezawa, T., Takeuchi, S., Hori, T., Sawa, M., Ishizuka, T., Ichikawa, and T., Komai, J. Antibiot. (Tokyo), 25, 409 (1972).
H., Umezawa, Lloydia, 40, 67 (1977).
M., Kanao, S. ,Tomita, S., Ishihara, A., Murakami, and H., Okada, Chemotherapy, 21, 1305 (1973).
K., Takahashi, O., Yoshioka, A., Matsuda, and H., Umezawa, J. Antibiot. (Tokyo), 30, 861 (1977).
A.,Kono, Chern. Pharm. Bull. (Tokyo), 25, 2882 (1977).
H., Umezawa, Y., Takahashi, A. Fujii, T., Saino, and T., Takita, J. Antibiot. (Tokyo), 26, 117 (1973).
T., Takita, A., Fujii, T., Fukuoka, and H., Umezawa,J. Antibiot. (Tokyo), 26, 252 (1973).
M., Konishi, K., Saito, K., Numata, T., Tsuno, K., Asama, H., Tsukiura, T., Naito, and H., Kawaguchi, J. Antibiot. (Tokyo) J. Antibiot. (Tokyo), 30, 789 (1977)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1979 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
Umezawa, H. (1979). Advances in Bleomycin Studies. In: Hect, S.M. (eds) Bleomycin: Chemical, Biochemical, and Biological Aspects. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-6191-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-4612-6191-9_2
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-6193-3
Online ISBN: 978-1-4612-6191-9
eBook Packages: Springer Book Archive